JP5684800B2 - 化合物 - Google Patents

化合物 Download PDF

Info

Publication number
JP5684800B2
JP5684800B2 JP2012513673A JP2012513673A JP5684800B2 JP 5684800 B2 JP5684800 B2 JP 5684800B2 JP 2012513673 A JP2012513673 A JP 2012513673A JP 2012513673 A JP2012513673 A JP 2012513673A JP 5684800 B2 JP5684800 B2 JP 5684800B2
Authority
JP
Japan
Prior art keywords
optionally substituted
formula
benzyl
oxo
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012513673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012528839A5 (enExample
JP2012528839A (ja
Inventor
ハムリン，リチャード，ジョン
マッジ，デーヴィッド
ムラ，ムスタク
ハルトゾウラキス，バジル
ジョーンズ，シモン，マーク
ジョン，デレク，エドワード
Original Assignee
ゼンション リミテッド
ゼンション リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゼンション リミテッド, ゼンション リミテッド filed Critical ゼンション リミテッド
Publication of JP2012528839A publication Critical patent/JP2012528839A/ja
Publication of JP2012528839A5 publication Critical patent/JP2012528839A5/ja
Application granted granted Critical
Publication of JP5684800B2 publication Critical patent/JP5684800B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2012513673A 2009-06-04 2010-06-04 化合物 Active JP5684800B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0909671.0A GB0909671D0 (en) 2009-06-04 2009-06-04 Compounds
GB0909671.0 2009-06-04
PCT/GB2010/001092 WO2010139953A1 (en) 2009-06-04 2010-06-04 Compounds

Publications (3)

Publication Number Publication Date
JP2012528839A JP2012528839A (ja) 2012-11-15
JP2012528839A5 JP2012528839A5 (enExample) 2013-07-18
JP5684800B2 true JP5684800B2 (ja) 2015-03-18

Family

ID=40936942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513673A Active JP5684800B2 (ja) 2009-06-04 2010-06-04 化合物

Country Status (5)

Country Link
US (1) US8399481B2 (enExample)
EP (1) EP2438044B1 (enExample)
JP (1) JP5684800B2 (enExample)
GB (1) GB0909671D0 (enExample)
WO (1) WO2010139953A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2720368T3 (es) 2008-03-27 2019-07-19 Purdue Research Foundation Peptidoglicanos sintéticos de enlace a colágeno, preparación y método de utilización
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds
LT2714718T (lt) * 2011-05-24 2017-04-10 Symic Ip, Llc Hialurono rūgštį surišantys sintetiniai peptidoglikanai, gamyba ir panaudojimo būdai
JP6603650B2 (ja) 2013-03-15 2019-11-06 パーデュー・リサーチ・ファウンデーション 細胞外マトリックス結合性合成ペプチドグリカン
WO2015164822A1 (en) 2014-04-25 2015-10-29 Purdue Research Foundation Collagen binding synthetic peptidoglycans for treatment of endothelial dysfunction
WO2018010142A1 (en) * 2016-07-14 2018-01-18 Shanghai Meton Pharmaceutical Co., Ltd Iso-citrate dehydrogenase (idh) inhibitor
EP3315551B1 (en) * 2016-10-25 2021-03-03 Borealis AG Heterophasic polypropylene composition with improved mechanical and optical properties
KR20240148963A (ko) 2017-07-07 2024-10-11 시믹 아이피, 엘엘씨 합성 생체접합체
CN114555597B (zh) * 2019-10-12 2024-06-04 浙江迈同生物医药有限公司 异柠檬酸脱氢酶（idh）抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US6083986A (en) * 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
US6077680A (en) 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
AU2004276268B2 (en) * 2003-09-23 2009-01-29 Merck Sharp & Dohme Corp. Isoquinoline potassium channel inhibitors
KR100793095B1 (ko) 2003-10-01 2008-01-10 주식회사 프로메디텍 Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
AU2005265270B2 (en) * 2004-06-22 2011-09-22 Vertex Pharmaceuticals Incorporated Heterocyclic derivatives for modulation of calcium channels
US20100160304A1 (en) 2005-01-19 2010-06-24 Dainippon Sumitomo Pharma Co., Ltd Aromatic sulfone compound as aldosterone receptor modulator
CA2620171A1 (en) 2005-08-25 2007-03-01 Schering Corporation Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
WO2007056078A2 (en) 2005-11-02 2007-05-18 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US8110681B2 (en) * 2006-03-17 2012-02-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compounds for the treatment of spinal muscular atrophy and other uses
DE102006013957A1 (de) 2006-03-27 2007-10-04 Bayer Healthcare Aktiengesellschaft Substituierte N-Benzyl-N-phenylbenzolsulfonamide
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
DE102007012284A1 (de) 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0710844D0 (en) 2007-06-06 2007-07-18 Lectus Therapeutics Ltd Potassium ion channel modulators & uses thereof
GB0815782D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0815784D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
GB0909672D0 (en) * 2009-06-04 2009-07-22 Xention Discovery Ltd Compounds

Also Published As

Publication number Publication date
EP2438044A1 (en) 2012-04-11
US8399481B2 (en) 2013-03-19
EP2438044B1 (en) 2019-01-23
US20110136859A1 (en) 2011-06-09
GB0909671D0 (en) 2009-07-22
JP2012528839A (ja) 2012-11-15
WO2010139953A1 (en) 2010-12-09

Similar Documents

Publication Publication Date Title
JP5684800B2 (ja) 化合物
JP5792619B2 (ja) 新規なカリウムチャネルブロッカー
JP6328193B2 (ja) 新規なカリウムチャネルブロッカー
JP5798032B2 (ja) 新規なカリウムチャネルブロッカー
CN104968647A (zh) 作为钠通道调节剂的酰胺
JP6100346B2 (ja) カリウムチャネル阻害剤として有用なジヒドロインドールおよびテトラヒドロイソキノリン誘導体
JP2006519258A (ja) ピリジン、ピリミジン、キノリン、キナゾリンおよびナフタレン系のウロテンシン−ｉｉ受容体拮抗薬
JP2008518889A (ja) 新規ブラジキニンｂ１アンタゴニスト、それらの製造方法及び薬物としてのそれらの使用
JP2007533635A (ja) バニロイド受容体リガンドおよび治療おけるこれらの使用
CA3008614A1 (en) Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels
JP2007522233A (ja) バニロイド受容体リガンド及び治療におけるそれらの使用
WO2019178324A1 (en) Amino-benzoisothiazole and amino-benzoisothiadiazole amide compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130531

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141216

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150115

R150 Certificate of patent or registration of utility model

Ref document number: 5684800

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250